Latest Breaking News On - Thomas biegi - Page 7 : comparemela.com

MorphoSys Reports Preliminary Q3 2023 Monjuvi U S Sales and Gross Margin, and Updates Financial Gui

EQS-News: MorphoSys AG / Key word(s): Change in ForecastMorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 25.10.2023 / 10:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Planegg/Munich, Germany, October 25, 2023 Mo.

United statesJean paul kressThomas biegiJulia neugebauerKaitlyn nealyExchange commissionDistribution servicesGross marginUpdates financial guidanceProduct salesPreliminary gross marginChief executive officerMorphosy annual reportCorporate newsRegulatory announcements

MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, September 12, 2023 MorphoSys Receiv.

United statesThomas biegiJulia neugebauerTim demuthEamonn nolanLymphoma societyDevelopment officerDistribution servicesExchange commissionXencor incDrug administrationAmerican society of clinical oncologyTrack designationEndometrial cancerFast trackClinical oncology

MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergEamonn nolanTim demuthJulia neugebauerThomas biegiXencor incDrug administrationExchange commissionDevelopment officerLymphoma societyAmerican society of clinical oncologyFast trackClinical oncologyAnnual meetingMorphosys chief research

EQS-News: MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmime.

United statesEamonn nolanJulia neugebauerTim demuthThomas biegiXencor incExchange commissionDrug administrationAmerican society of clinical oncologyLymphoma societyDevelopment officerTrack designationFast trackClinical oncologyAnnual meetingMorphosys chief research

MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys Receives U S FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJulia neugebauerThomas biegiTim demuthEamonn nolanAmerican society of clinical oncologyDrug administrationExchange commissionLymphoma societyXencor incDevelopment officerFast trackClinical oncologyAnnual meetingMorphosys chief researchAntibody dependent cell mediated cytotoxicity